AU2005335241B9 - Methods for treating substance-related disorders - Google Patents

Methods for treating substance-related disorders Download PDF

Info

Publication number
AU2005335241B9
AU2005335241B9 AU2005335241A AU2005335241A AU2005335241B9 AU 2005335241 B9 AU2005335241 B9 AU 2005335241B9 AU 2005335241 A AU2005335241 A AU 2005335241A AU 2005335241 A AU2005335241 A AU 2005335241A AU 2005335241 B9 AU2005335241 B9 AU 2005335241B9
Authority
AU
Australia
Prior art keywords
formula
enantiomer
withdrawal
use according
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005335241A
Other languages
English (en)
Other versions
AU2005335241A1 (en
AU2005335241B2 (en
Inventor
Carlos R. Plata-Salaman
Roy E. Twyman
Boyu Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of AU2005335241A1 publication Critical patent/AU2005335241A1/en
Assigned to SK BIOPHARMACEUTICALS CO., LTD. reassignment SK BIOPHARMACEUTICALS CO., LTD. Request for Assignment Assignors: JANSSEN PHARMACEUTICA, N.V.
Publication of AU2005335241B2 publication Critical patent/AU2005335241B2/en
Application granted granted Critical
Publication of AU2005335241B9 publication Critical patent/AU2005335241B9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2005335241A 2005-07-26 2005-07-26 Methods for treating substance-related disorders Ceased AU2005335241B9 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/026439 WO2007018496A1 (en) 2005-07-26 2005-07-26 Methods for treating substance-related disorders

Publications (3)

Publication Number Publication Date
AU2005335241A1 AU2005335241A1 (en) 2007-02-15
AU2005335241B2 AU2005335241B2 (en) 2012-11-15
AU2005335241B9 true AU2005335241B9 (en) 2012-12-20

Family

ID=35064669

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005335241A Ceased AU2005335241B9 (en) 2005-07-26 2005-07-26 Methods for treating substance-related disorders

Country Status (13)

Country Link
EP (1) EP1928451B1 (enExample)
JP (1) JP5094720B2 (enExample)
KR (1) KR101199499B1 (enExample)
CN (1) CN101272776B (enExample)
AT (1) ATE538784T1 (enExample)
AU (1) AU2005335241B9 (enExample)
BR (1) BRPI0520451A2 (enExample)
CA (1) CA2616721C (enExample)
EA (1) EA019935B1 (enExample)
ES (1) ES2385087T3 (enExample)
IL (1) IL189003A0 (enExample)
NO (1) NO20080877L (enExample)
WO (1) WO2007018496A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1890684T3 (pl) 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
WO2011005473A2 (en) 2009-06-22 2011-01-13 Shionogi Pharma, Inc. Methods for treating or preventing fatigue
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
ES2447295T3 (es) 2009-11-06 2014-03-11 Sk Biopharmaceuticals Co., Ltd. Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
RU2557533C2 (ru) 2009-11-06 2015-07-20 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома фибромиалгии
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
BR112015022197B1 (pt) 2013-03-13 2022-06-07 Sk Biopharmaceuticals Co., Ltd. Uso de um composto para o tratamento de cataplexia
CN105873576B (zh) 2013-07-18 2019-07-19 爵士制药国际Iii有限公司 治疗肥胖
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
KR20240162165A (ko) 2017-06-02 2024-11-14 재즈 파마슈티칼즈 아일랜드 리미티드 과다 졸림증을 치료하기 위한 방법 및 조성물
JP7257091B2 (ja) * 2019-06-27 2023-04-13 沼澤 敏彦 認知症の治療及び予防薬
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
WO2002067926A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating movement disorders
WO2002067927A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating psychotic disorders
US20040171679A1 (en) * 2001-02-27 2004-09-02 Plata-Salaman Carlos R. Carbamate compounds for use in preventing or treating neurodegenerative disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0207832A (pt) * 2001-02-27 2004-06-22 Ortho Mcneil Pharm Inc Compostos de carbamato para uso na prevenção ou tratamento de distúrbio bipolar
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
WO2002067926A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating movement disorders
WO2002067927A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating psychotic disorders
US20040171679A1 (en) * 2001-02-27 2004-09-02 Plata-Salaman Carlos R. Carbamate compounds for use in preventing or treating neurodegenerative disorders

Also Published As

Publication number Publication date
AU2005335241A1 (en) 2007-02-15
ATE538784T1 (de) 2012-01-15
EP1928451A1 (en) 2008-06-11
CN101272776B (zh) 2012-10-03
AU2005335241B2 (en) 2012-11-15
JP2009502914A (ja) 2009-01-29
IL189003A0 (en) 2008-11-03
NO20080877L (no) 2008-02-19
BRPI0520451A2 (pt) 2009-05-12
EP1928451B1 (en) 2011-12-28
EA019935B1 (ru) 2014-07-30
KR20080037055A (ko) 2008-04-29
ES2385087T3 (es) 2012-07-18
WO2007018496A1 (en) 2007-02-15
JP5094720B2 (ja) 2012-12-12
EA200800422A1 (ru) 2008-10-30
KR101199499B1 (ko) 2012-11-09
CA2616721A1 (en) 2007-02-15
CN101272776A (zh) 2008-09-24
CA2616721C (en) 2014-01-21

Similar Documents

Publication Publication Date Title
CA2764665C (en) Compositions for treating drug addiction and improving addiction-related behavior
JP5901528B2 (ja) 線維筋痛症候群の治療方法
AU2005335241B9 (en) Methods for treating substance-related disorders
RU2294739C2 (ru) Производные карбамата для применения для предупреждения или лечения расстройств движений
MXPA03007716A (es) Compuestos de carbamato para su uso en la prevencion o tratamiento de trastornos bipolares.
JP2004533415A (ja) 双極性障害の予防もしくは治療における使用のためのカルバメート化合物
AU2002242296B2 (en) Carbamate compounds for use in preventing or treating psychotic disorders
NZ565188A (en) The use of carbamate derivatives to treat drug withdrawal disorders
AU2002322442B2 (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
HK1209058B (en) Compositions for treating drug addiction and improving addiction-related behavior
HK1176285B (en) Compositions for treating drug addiction and improving addiction-related behavior
HK1063435A1 (en) Carbamate compounds for use in preventing or treating neuropathic pain

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SK BIOPHARMACEUTICALS CO., LTD.

Free format text: FORMER APPLICANT(S): JANSSEN PHARMACEUTICA, N.V.

SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired